EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Intermittent Fasting as a Treatment for Nonalcoholic Fatty Liver Disease: What Is the Evidence?

Zoe N Memel, Jeffrey Wang, Kathleen E Corey

Clinical Liver Disease · 2022-03 · 19 (3) · 101-105

DOI: 10.1002/cld.1172 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Liver Disease, online erschienen am 03.02.2022. Verfasst von Zoe N Memel und 2 weiteren Autor:innen. Beteiligte Einrichtung: Harvard Medical School Boston MA. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Harvard Medical School Boston MA.
  • Department of Medicine Massachusetts General Hospital Boston MA.
  • Liver Center and Gastrointestinal Division Massachusetts General Hospital Boston MA.

Zitieren

APA

Memel, Z. N., Wang, J., & Corey, K. E. (2022). Intermittent Fasting as a Treatment for Nonalcoholic Fatty Liver Disease: What Is the Evidence?. Clinical Liver Disease, 19(3), 101-105. https://doi.org/10.1002/cld.1172

Vancouver

Memel ZN, Wang J, Corey KE. Intermittent Fasting as a Treatment for Nonalcoholic Fatty Liver Disease: What Is the Evidence?. Clinical Liver Disease. 2022;19(3):101-105. doi:10.1002/cld.1172

BibTeX
@article{Memel2022,
  author = {Memel, Zoe N and Wang, Jeffrey and Corey, Kathleen E},
  title = {Intermittent Fasting as a Treatment for Nonalcoholic Fatty Liver Disease: What Is the Evidence?},
  journal = {Clinical Liver Disease},
  year = {2022},
  volume = {19},
  number = {3},
  pages = {101--105},
  doi = {10.1002/cld.1172}
}
Kostenlos starten →